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Abstract Targeted therapy has significantly improved the
perspectives of patients with metastatic renal cell cancer
(mRCC). Frequently, these new molecules cause disease
stabilization rather than substantial tumor regression. As
treatment options expand with the growing number of
targeted agents, there is an increasing need for surrogate
markers to early assess tumor response. Here, we review
the currently available imaging techniques and response
evaluation criteria for the assessment of tumor response in
mRCC patients. For computed tomography (CT), different
criteria are discussed including the Response Evaluation
Criteria in Solid Tumors (RECIST), the Choi criteria, the
modified Choi criteria, and the size and attenuation CT
(SACT) criteria. Functional imaging modalities are dis-
cussed, such as dynamic contrast-enhanced CT (DCE-CT),
dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI), dynamic contrast-enhanced ultrasonography
(DCE-US), and positron emission tomography (PET).
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Response evaluation . Targeted therapy
Introduction
Renal cell carcinoma (RCC) is the thirteenth most common
cancer worldwide, accounting for more than 208,000 new
diagnoses and 102,000 deaths per year [1]. Approximately
one third of patients present with metastatic disease at the
time of diagnosis. In addition, about 30% of all other
patients will develop metastases at a later stage of their
disease. For decades, the treatment options for patients with
metastatic renal cell cancer (mRCC) have been very
limited, as RCC in general is not sensitive to chemotherapy.
Since the early 1990’s, cytokine-based therapy consisting of
interferon-α and/or interleukin-2 represented the only
approach for systemic therapy of mRCC [2]. Although
some patients may obtain long-lasting complete remissions
upon cytokine therapy, responses in most mRCC patients
are modest. In the past 5 years, molecular therapy has
shown relevant efficacy in mRCC, providing new hope for
mRCC patients [3]. Currently, targeted agents have
replaced immunotherapy with cytokines in the majority of
mRCC cases.
Increasing knowledge of the underlying biology of RCC,
and more specifically, the clear cell subtype, has identified
interesting signaling pathways for targeted therapy. Sixty
percent of clear cell carcinomas, a subtype accounting for
75% of all RCC, appear to contain an inactivated von
Hippel–Lindau (VHL) tumor suppressor gene. Alterations
in the VHL gene cause elevated protein levels of hypoxia-
inducible factor-1α (HIF-1α), which upregulates vascular
endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF) genes and proteins [4]. Consequent-
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ly, the overexpression of these growth factors results in
tumor angiogenesis [5] and extensive vascularization of
RCC. Therefore, tumor angiogenesis has become an
important focus of targeted therapy for RCC. The main
classes of targeted agents for RCC are small molecules
directed against receptor tyrosine kinases and monoclonal
antibodies, both inhibiting signaling via the VEGF route.
Several antiangiogenic drugs, including bevacizumab
[6], sorafenib [7], sunitinib [8], axitinib [9, 10], and
pazopanib [11] have demonstrated significant efficacy in
mRCC. In a phase III clinical trial in mRCC, a combination
of interferon-α with bevacizumab, the neutralizing antibody
of VEGF, improved progression-free survival (PFS) with
almost 5 months as compared to interferon-α alone [12].
Sunitinib, sorafenib, axitinib, and pazopanib are oral
tyrosine kinase inhibitors (TKIs) of multiple receptors (R),
including VEGFRs and PDGFRs. Although these TKIs
have an overlapping mechanism of action, distinct differ-
ences are based on binding characteristics and their capacity
to inhibit other targets. In comparison with placebo,
sorafenib improved PFS in cytokine-pretreated mRCC with
almost 3 months [7]. Sunitinib has demonstrated a
significantly prolonged PFS (11 versus 5 months) as well
as a higher objective response rate as compared with
interferon-α (best tumor response 47% versus 12%) in
treatment-naive mRCC patients [13]. In addition, pazopanib
significantly improved PFS and objective response rate as
compared to placebo in a patient population consisting of
treatment-naive and cytokine-pretreated patients (median
PFS, 9 months versus 4 months; objective response rate,
30% versus 3%) [11].
Besides inhibition of VEGF signaling, the mammalian
target of rapamycin (mTOR) is another important therapeu-
tic target in RCC, although its mechanisms of activation are
not yet fully understood. mTOR may play a role in the
development of RCC and is associated with elevated HIF
activity [14]. mTOR inhibitors seem to down-regulate HIF
activity primarily when the mTOR pathway is abnormally
activated [15, 16]. Temsirolimus and everolimus as inhib-
itors of the mTOR pathway have demonstrated significant
antitumor activity in RCC. Temsirolimus prolonged the
overall survival (OS) in poor-risk mRCC patients as
compared to interferon-α (11 months versus 7 and 8 months
for, respectively, single-agent temsirolimus versus single-
agent interferon-α and the combination) [17], whereas
everolimus improved PFS as compared to placebo in
patients with advanced RCC who had failed treatment with
either sorafenib or sunitinib (4 months versus 2 months)
[18].
Frequently, targeted molecules cause disease stabiliza-
tion rather than substantial tumor regression in mRCC
patients. For instance, treatment with sorafenib and temsir-
olimus is associated with low response rates (≤10%),
despite significant improvement of OS [7, 17]. Of interest,
TKIs are known to induce early and extensive necrosis
(Fig. 1) without a substantial decrease in tumor size [10,
19–22] and may even simulate progressive disease (PD), as
treatment-induced necrosis may be accompanied by an
increase in tumor size. Presently, response to targeted
therapy is usually assessed by Response Evaluation Criteria
in Solid Tumors (RECIST) [23], which is the most widely
used measurement system in clinical trials. However,
RECIST may underestimate objective responses during
targeted therapy [24], as it is only based on the sum of the
longest diameters of the appointed target lesions in the
transversal plane [23] and does not account for other drug-
induced morphological changes.
Currently, several targeted agents have been approved
for the treatment of mRCC that have significantly improved
the perspectives of patients with mRCC. Nevertheless,
treatments with these drugs fail in a number of these
patients. In addition, targeted therapy is associated with a
wide range of drug-induced toxicities that can be severe
[24]. As treatment options expand with the growing number
of targeted agents, there is an increasing need for surrogate
markers to early assess tumor response. Here, we review
the currently available imaging techniques and response
evaluation criteria for the assessment of drug-induced
Fig. 1 Primary tumor at base-
line a and after two cycles of
sunitinib demonstrating a de-
crease in size as well as in
attenuation due to the develop-
ment of necrosis b [21]
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tumor response in mRCC patients. For computed tomogra-
phy (CT), different criteria are discussed including
RECIST, the Choi criteria, the modified Choi criteria, and
the size and attenuation CT (SACT) criteria. In addition,
functional imaging modalities are discussed, such as
dynamic contrast-enhanced CT (DCE-CT), dynamic
contrast-enhanced magnetic resonance imaging (DCE-
MRI), dynamic contrast-enhanced ultrasonography (DCE-
US), and positron emission tomography (PET).
Computed tomography
Response evaluation criteria in solid tumors
Assessment of morphological changes, i.e., changes in
tumor size burden, is an important evaluation method to
determine the effect of anticancer drugs. Currently, RECIST
is the most commonly used measurement system [23].
RECIST is a one-dimensional method and is based on the
sum of the longest diameters of the appointed target lesions
in the transversal plane. To determine tumor response
accurately, target lesions (≥10 mm) are usually identified on
CT or magnetic resonance imaging (MRI). According to
RECIST, chest X-ray may also be considered instead of CT
if lesions are clearly defined, have a diameter of at least
20 mm, and are surrounded by aerated lung. However,
chest CT is preferred over chest X-ray, as CT is more
sensitive than X-ray, especially in identifying new lesions.
RECIST provides four classes to determine the objective
tumor response for target lesions (Table 1). Briefly, complete
response (CR) is defined as disappearance of all target
lesions, whereas a partial response (PR) requires a decrease
in the sum of diameters of at least 30%, taking as reference
the sum of the diameters at baseline. The appearance of new
lesions or at least a 20% increase in the sum of the diameters
is classified as PD, taking as reference the smallest sum
during treatment. When the changes in the sum of the
diameters are not sufficient to qualify for PR or PD, the
objective response is defined as stable disease (SD).
Recently, RECIST has been updated and version 1.1 has
been introduced in the clinic [23]. As compared to the old
version 1.0 [25], notable changes include a reduction in the
number of target lesions to be assessed per patient (from a
maximum of 10 to a maximum of 5) and per organ (from 5
to 2 per organ), a change in assessment of pathological
lymph nodes (measurement of the longest axis has been
changed into the shortest; nodes should have a short axis of
≥15 mm to be considered as measurable) and the clarifica-
tion of disease progression in small tumor burden (a 5 mm
absolute increase is now required).
Many studies have applied RECIST to determine
response to targeted therapy in mRCC [7, 8, 18]. Best
response may take several months [8, 13], and is occasion-
ally achieved up to 10 months after the start of treatment
[22]. In a previous study in 55 mRCC patients treated with
sunitinib, 13% of patients had PR, 69% of patients had SD,
and 18% of patients had PD at a median of 1.9 months after
the start, but 18% of patients with initial SD reached a PR
at later time-points (median time to PR: 3.9 months; range:
2.4–9.7 months) [22]. Therefore, with the use of RECIST at
first evaluation in patients with SD it cannot be discrimi-
nated which patients will have PD at the next time-point in
order to timely change the type of treatment, since some
patients benefit from continued SD and some patients may
even reach a PR.
Size variation for response evaluation
Since the expected effect of targeted agents in mRCC
would be stabilization rather than substantial tumor regres-
sion, PR according to RECIST may not be accurate in the
era of targeted therapy. Therefore, Thiam et al. [26] have
attempted to determine a threshold for CT evaluation that
best reflected treatment outcome. With PFS as the primary
outcome, thresholds from −45% to +10% were tested in
334 mRCC patients treated with sunitinib. A decrease of at
least 10% in the sum of the longest diameters was identified
as the most accurate threshold to distinguish responders (n
=256) from non-responders (n=78). Already during the
first treatment cycle, 73% of patients reached a response
according to the −10% threshold, whereas only 19% of
patients reached a PR according to RECIST (≥30%
decrease). After the second treatment cycle, the −10% and
−30% thresholds were achieved in 93% en 64% of the
patients. This study shows that responders can be earlier
identified with the −10% threshold than with the conven-
tional threshold of −30% according to RECIST.
Contrast-enhanced computed tomography
Impressive changes in tumor attenuation have been ob-
served during targeted therapy as visualized by contrast-
enhanced CT. The contrast-enhancement on CT is directly
related to tumor angiogenesis [27–29]. In metastases from
RCC, higher pretreatment values of contrast-enhancement
are associated with a higher response rate to targeted
therapy consisting of either sunitinib or sorafenib [30],
allowing prediction of outcomes of individual metastatic
lesions before the start of targeted therapy. In addition,
treatment-induced changes in tumor density are associated
with response to therapy and the development of necrotic
areas [31]. In contrast, the development of a marked central
fill-in and new enhancement in homogeneously, hypo-
attenuating, non-enhancing RCC lesions are commonly
seen at or just before the time of progression late in the
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course of treatment [32], suggesting that an increase in
contrast-enhancement may be associated with disease
progression. Currently, three different response evaluation
criteria that incorporate changes in contrast-enhancement
have been investigated in mRCC patients: the Choi criteria,
the modified Choi criteria, and the size and attenuation CT
(SACT) criteria (Table 1).
Choi criteria
Using contrast-enhanced CT scans, Choi et al. [33, 34] have
developed new evaluation criteria to determine the efficacy
of imatinib in patients with gastrointestinal stromal cell
tumors (GIST). In patients with GIST, imatinib is known to
induce extensive tumor necrosis that may be accompanied
by an increase in tumor size and may even simulate PD
[34]. The Choi criteria include changes in tumor attenuation
expressed as Hounsfield Units (HU) on contrast-enhanced
CT. The threshold for changes in tumor attenuation on CT
is based on a decrease of the maximum standardized uptake
value (SUVmax) of at least 70% as measured by positron
emission tomography (PET) using 2-[18F]fluoro-2-deoxy-
D-glucose ([18F]FDG). According to Choi et al. [33, 34], a
PR is defined as a ≥10% decrease in one-dimensional tumor
size or a ≥15% decrease in tumor attenuation on contrast-
enhanced CT scan, while PD is defined as a ≥10% increase
in size without meeting PR criteria by change in attenuation
(Table 1). Lesions with a longest diameter ≥15 mm are
eligible for measurements according to the Choi criteria. In
imatinib-treated patients with GIST, the Choi criteria had a
significantly better correlation with disease-specific surviv-
al than RECIST.
Recently, we have evaluated the Choi criteria in 55
mRCC patients who were treated with sunitinib [22].
During sunitinib treatment, the median tumor attenuation
decreased from 66 to 47 HUs. According to the Choi
criteria, 36 (65%) patients achieved a PR, 6 (11%) patients
had SD and 13 (24%) patients had PD at first evaluation. In
19 out of 36 responders, the achieved PR was only based
on a decrease in tumor attenuation ≥15%. Patients with a
PR according to Choi criteria had a prolonged PFS and OS
as compared to patients without a PR. At first evaluation,
the Choi criteria had a significantly better predictive value
for PFS and OS than RECIST. However, the predictive
value of the Choi criteria was similar to that of RECIST at
later time-points. The Choi criteria were not able to early
identify patients with PD. Therefore, we concluded that the
Choi criteria will not change the clinical management of
mRCC patients treated with sunitinib.
The Choi criteria may be more useful to identify mRCC
patients with PD during sorafenib treatment, as sorafenib is
associated with extensive necrosis [35] and fewer patients
have tumor response to sorafenib as compared to sunitinib
[32]. Two studies have described less favorable results for
the use of the Choi criteria in comparison with RECIST in
mRCC patients [32, 36]. In these analyses, however, fewer
mRCC patients were included [36], different TKIs were
administered (sunitinib, sorafenib, and cediranib) [32, 36],
lung lesions were excluded for attenuation measurements
[32], and attenuation measurements were based on volu-
metric data instead of two-dimensional data acquired in
most representative axial images [32].
Modified Choi criteria
Nathan et al. [36] have compared the Choi criteria with the
modified Choi criteria in which changes in both size and
attenuation of target lesions have to be calculated to define
an objective response (Table 1). In that study, CT scans
from 32 mRCC patients who were treated with either
sunitinib or cediranib were evaluated. Ten patients needed
to be excluded from further analysis because of non
contrast-enhanced CT scans due to renal impairment.
Ultimately, 20 patients were evaluable of whom 5, 19,
and 13 patients achieved a PR according to, respectively,
RECIST, the Choi criteria, and the modified Choi criteria.
The group concluded that the modified Choi criteria
provided the best segregation of the median time-to-
progression.
Size and attenuation CT (SACT) criteria
As a ≥10% decrease in tumor size or a ≥15% decrease in
tumor attenuation is not necessarily associated with a
prolonged PFS, the size and attenuation CT (SACT) criteria
have been developed (Table 1) [32]. According to these
criteria a favorable response is defined as a decrease in tumor
size of ≥20% or a decrease in mean attenuation of ≥40 HU in
at least one non-lung target lesion. In case patients have a
decrease in tumor size of ≥10% and a decrease in mean
attenuation of ≥20 HU in half of the non-lung target lesions,
they are also classified as favorable responders. Patients have
an unfavorable response in case of an increase in tumor size
of ≥20% or the development of new lesions. Patients also
have an unfavorable response in case of new enhancement in
a homogeneously hypo-attenuating non-enhancing lesion or
in case of a marked change from central necrosis to near
complete enhancement of solid parts in the central area of the
tumor. According to the SACT criteria, mean attenuation
measurements are based on volumetric measurements. Lung
lesions are not eligible because of inconsistent mean
attenuation results from averaging between soft tissue and
air. This is a potential limitation for the use of SACT criteria
in mRCC patients as the lung is a common metastatic site.
The use of absolute changes instead of percentage changes in
tumor attenuation is a potential advantage of the SCAT
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criteria as compared to the Choi and the modified Choi
criteria, since a 15% decrease in attenuation is reached early
in lesions with low baseline values and may therefore result
in less accurate measurements.
Limitations of contrast-enhanced measurements in RCC
Although incorporation of changes in tumor attenuation
appears to be valuable for response assessment, several
limitations should be mentioned for its use in mRCC patients
who are treated with targeted agents. A series of requirements
have to be taken into account, such as identical scanning
protocols and the same timing of intravenous contrast (IV)
between the subsequent CT scans, as slightly different phases
in IV contrast may result in incorrect changes in lesion
attenuation. It should also be considered that targeted agents
may affect the cardiac output [37], because of which the
distribution of IV contrast may change during treatment
despite the use of an identical scanning protocol. Addition-
ally, contrast-enhanced CT scanning may not be possible in a
number of mRCC patients, since administration of IV
contrast may be contraindicated in case of an impaired renal
function [36].
Dynamic contrast-enhanced CT (DCE-CT)
As the measurement of contrast-enhancement on CT does
not provide quantitative measurement of kinetic variables,
such as the contribution of flow, dynamic imaging by CT
may be more appropriate to evaluate these variables during
targeted therapy. Dynamic contrast-enhanced CT (DCE-CT
or CTP) is a functional perfusion CT that provides
estimations of the tissue perfusion parameters blood flow
(BF), blood volume (BV), mean transit time (MTT), and
capillary permeability surface area (PS). After IV injection
of a freely diffusible iodine-based contrast agent, dynamic
CT scanning is performed of a selected field of view in
which the lesion of interest is localized. Using CT perfusion
software, the tissue perfusion parameters (BF, BV, MTT,
and PS) can be estimated.
Few clinical studies have used DCE-CT to measure
response to therapy [38–41] and none thus far in mRCC
patients receiving targeted therapy. In various solid tumors,
DCE-CT has shown a reduction in perfusion during anti-
angiogenic therapy [38, 39]. In 12 patients with colorectal
cancer, DCE-CT demonstrated anti-vascular effects within
7 days after administration of bevacizumab [38].
In 33 bevacizumab-treated patients with hepatocellular
carcinoma, DCE-CT has been performed at baseline and on
days 10–12 [41]. In 23 evaluable patients, significant
decreases in BF, BV, and PS were observed, while an
increase in MTT was calculated. In 21 hepatocellular
carcinoma patients DCE-CT could be related to clinical
outcome. Patients with PD had lower baseline MTT values
and a higher percent increase following bevacizumab
administration than those with SD or PR. As enhancement
parameters of dynamic CT correlate with microvessel
density (MVD) in RCC [42], DCE-CT may have additional
value for early assessment of tumor response to targeted
therapy. A disadvantage of DCE-CT is the high radiation
burden, which limits its serial use for repeated response
assessments.
Magnetic resonance imaging (MRI)
Dynamic contrast-enhanced MRI (DCE-MRI)
DCE-MRI is widely used in the diagnosis and staging of
cancer and is emerging as a promising method for
monitoring tumor response to targeted therapy [43, 44].
Quantitative T1-weighted images of the microvasculature
are obtained by tracking the pharmacokinetics of an IV
bolus of a gadolinium-containing contrast agent, which is
freely diffusible between the intravascular and the extracel-
lular extravascular space. Gadolinium ions are paramagnet-
ic and shorten the T1-relaxation times in tissue water by
interaction with nearby hydrogen nuclei. In a T1-weighted
DCE-MRI, the tumor enhancement over time reflects the
delivery of the gadolinium contrast into the tumor tissue.
Although DCE-MRI imaging protocols differ, three types
of imaging data are usually acquired. The first images are
used for localization of the tumor. Thereafter, sequences are
acquired that are used to calculate the baseline T1-values
which are necessary for the analysis. At last, dynamic
imaging data are acquired for about 5–10 min after
gadolinium injection [44].
Data analysis of DCE-MRI is complex, as the
obtained variables are mainly dependent on the acquisi-
tion protocol and the method for data analysis [45]. In
addition, no consensus has been reached on the kinetic
model to be used for the analysis of DCE-MRI data to
measure the efficacy of targeted agents. The various
acquisition and analysis methods have considerable
influence on the interpretation of the obtained variables
and their value as surrogate end-points for targeted
therapy. For pharmacokinetic modeling of contrast agent
uptake, a compartment model is commonly used to
estimate three physiological parameters including the
volume transfer constant Ktrans between the blood plasma
and extravascular extracellular space (EES) (min−1), the
volume of EES per unit volume of tissue and the flux rate
constant between EES and plasma (min−1) (Fig. 2). A
change in Ktrans of >40% is usually considered a true
difference caused by drug effect [45]. In addition, the area
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under the gadolinium concentration curve is another
frequently used parameter to determine treatment effects.
In a number of clinical studies in solid tumors, DCE-
MRI has been applied to monitor early response to targeted
therapy [46–48], particularly in mRCC [49–52]. In a phase
II trial in 17 mRCC patients, sorafenib treatment induced a
large decline in Ktrans of 60.3% [49]. The percentage
decline of Ktrans and the change in tumor size by CT scan
were significantly associated with PFS [49]. Additionally,
high tumor Ktrans before treatment was also significantly
associated with improved PFS [49]. In another DCE-MRI
study in 44 mRCC patients, four weeks after initiation of
placebo, sorafenib 200 mg×2 and sorafenib 400 mg×2, the
mean Ktrans log ratios had changed by, respectively, +14%,
−14% and −24% [50]. The changes in Ktrans were not
associated with PFS, but patients with a high Ktrans at
baseline had a prolonged PFS. The association between a
high Ktrans at baseline and a prolonged PFS is in line with
the results of the study by Flaherty et al. [49]. Remarkably,
the effects of sorafenib on DCE-MRI parameters appeared
to be highly variable across the tumor regions of interest
which suggests that a more detailed voxel-based analysis,
such as parametric images, might be more useful to analyze
sorafenib-treated RCC lesions.
Arterial spin labeling (ASL) MRI
ASL is an alternative for the measurement of tumor blood
flow by MRI and requires no external tracers [53, 54].
Labeling of arterial blood is achieved by spatially selective
inversion of the MRI signal of inflowing arterial blood. The
MRI signal from inverted blood is made negative relative to
uninverted blood. When the labeled blood with a negative
signal enters the tumor lesion, it attenuates the signal from
the image of that lesion. The difference between the labeled
image and the control image without labeling gives a
measure of blood flow. The ASL tracer is water and can
consequently be considered as highly diffusible.
In 10 mRCC patients treated with vatalanib, ASL MRI
already showed changes in tumor blood flow at 1 month on
treatment, while changes in size according to RECIST were
only measured at 4 months [55]. ASL MRI demonstrated a
significant decrease in blood flow (−42±22%) in mRCC
patients with SD or PR, whereas patients with PD had a
non-significant increase in tumor blood flow (+25±3%). As
ASL MRI does not involve administration of contrast
medium, the technique provides the opportunity of fre-
quently repeated measurements, particularly in RCC
patients with impaired renal function [56], and can be
applied to determine the optimal time-point for perfusion
measurement during antiangiogenic treatment.
Diffusion-weighted MRI (DW-MRI)
DW-MRI is another alternative to contrast-enhanced MRI, as
this technique does not require administration of contrast [57].
DW-MRI is sensitive to the random motion of water
molecules and allows for non-invasive characterization of
biological tissues on the basis of their water-diffusion
properties [58]. Highly cellular tissues can be differentiated
from acellular tissues, as diffusion of water molecules is
reduced in the cellular area in comparison with that in the
extracellular space. The degree of water diffusion within
tissues, or the apparent diffusion coefficient (ADC) in
mm2·s−1, can be calculated by acquiring multiple images
with different amplitudes or durations for the diffusion-
weighting gradients. Consequently, increased cellularity and
decreased interstitial space result in restriction of water
molecules and decreased ADC values. In tumors, DW-MRI
can be used to differentiate highly cellular from acellular
regions and to monitor changes in cellularity over time,
which reflects tumor response to therapy [59–63]. In
addition, ADC is a reproducible physical constant, which is
independent of scanner, magnetic field and operator. How-
ever, there are some limitations with regard to the placement
of regions of interest (ROI) on ADC maps caused by poor
resolution, which results in partial volume effects.
In RCC, DW-MRI has been mainly evaluated for
characterization of primary tumors [57, 64–68]. In these
studies, ADC values of high-grade clear cell carcinomas were
lower than those of low-grade clear cell carcinomas [66],
whereas ADC values of non-clear cell carcinomas were
higher than those of the clear cell subtype [64]. The
experience with DW-MRI in monitoring of mRCC during
treatment is limited [69] and studies are warranted to
substantiate the use of DW-MRI as a biomarker for response
to targeted therapy in mRCC.
Dynamic contrast-enhanced ultrasonography (DCE-US)
DCE-US is a functional imaging technique that can be used
to detect microvessels and quantitatively assess tumor
perfusion of solid tumors [70–72]. DCE-US requires
Doppler ultrasound and a microbubble contrast agent,
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Fig. 2 A tracer kinetic model for the analysis of dynamic gadolinium-
enhanced magnetic resonance imaging (MRI) is used to estimate 3
physiologic parameters: volume transfer constant (Ktrans) between
blood plasma and extravascular extracellular space (EES), volume of
EES per unit volume of tissue (υe), and flux rate constant between the
EES and plasma, .ep .ep ¼ Ktrans=ue
 
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which enhances the vessel signal and enables detection of
blood vessels with a diameter as small as 40 μm [73]. The
microbubbles remain in the intravascular compartment and
are not subjected to extra-vascular diffusion. DCE-US
provides both morphological and functional perfusion data.
Semi-quantitative perfusion measurements can be obtained
from the time-concentration curve. Quantitative data can be
obtained by analyzing the replenishment kinetics directly
after the sudden and local destruction of the phospholipid-
based microbubbles that encapsulate an inert gas [74]. The
quantitative analysis is performed on the contrast uptake
curve in the tumor which is constructed from raw linear
data [70]. Then 3 min of raw data are used for quantifica-
tion in order to obtain seven parameters: peak intensity (PI),
time to peak intensity (TPI), mean transit time (MTT),
coefficient of wash-in slope, area under the total curve, area
under the curve during the wash-in and area under the curve
during the wash-out [70] (Fig. 3). Of these parameters, the
slope of the time to peak intensity correlates with blood
flow, whereas the peak intensity and area under the curve
correlate with blood volume.
Thus far, a number of clinical trials with targeted agents
have incorporated DCE-US for imaging of lesions and
demonstrated that DCE-US parameters may be correlated
with tumor response [75–78]. In mRCC patients, the
usefulness of DCE-US was investigated during treatment
with sunitinib [76, 79] and sorafenib [75, 78] (Fig. 4). In 38
mRCC patients treated with sunitinib, the ratio between
DCE-US values at baseline and day 15 was significantly
different in responders (PR according to RECIST) and non-
responders (no PR according to RECIST) for five out of
seven DCE-US parameters: peak intensity (PI), area under
the total curve, area under the wash-out, time to peak
intensity, and slope of wash-in. In addition, the peak intensity
and the slope of the wash-in were significantly associated
with PFS [76]. An increase in the time to peak intensity
>29% and a decrease in the slope of the wash-in >76% were
associated with an increased PFS and OS [76]. In another
DCE-US study, 30 mRCC patients were treated with
sorafenib or placebo [75]. At 3 weeks of therapy, good
responders could be discriminated from non-responders
based on the combination of a decrease in contrast uptake
>10% and stability or decrease in tumor volume [75].
Although various RCC lesions (e.g., liver metastases and
abdominal lymph nodes) are accessible for DCE-US
measurements, DCE-US cannot be used for aerated lesions
in the lung, as ultrasound waves are disrupted by air or gas.
This is a potential limitation for the use of DCE-US in
mRCC, as the lung is a common metastastic site.
Advantages of DCE-US, however, include the low costs,
the low inter-operator variability [80], its ease of use, and
the possibility to repeat the measurements without adverse
effects, such as exposure to ionizing radiation. Currently,
the feasibility of DCE-US in monitoring antiangiogenic
treatment is evaluated in a French National Program in
which 650 patients with different malignancies will be
included and 4,800 examinations are planned [70]. DCE-
US will be performed at baseline and after 1, 7 and 15 days
and after 1 and 2 months, and then every 2 months. The
results of this large national study in which 18 French
institutions are involved may define the best DCE-US
parameter and the best time-point to assess the efficacy of
antiangiogenic treatment, and may reveal the best threshold
to differentiate between responders and non-responders.
Positron emission tomography (PET)
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG)
[18F]FDG PET is an important functional imaging tool in
oncology [81]. The use of [18F]FDG is based on the fact
that malignant tumor cells have a high glucose metabolism
and actively take up glucose and its analogue [18F]FDG.
The use of [18F]FDG PET in patients with RCC is limited
[82], since [18F]FDG PET has no major value for the
detection of renal masses [83] or RCC metastases [84, 85].
As RCC has only a low potential for metabolizing glucose
[86], a negative [18F]FDG PET does not rule out the
presence of RCC. A positive [18F]FDG PET in RCC
patients, however, is predictive for the presence of a RCC
lesion [87, 88] and may complement anatomic imaging
modalities, such as CT or may even be used in combination
with CT [89].
When RCC is [18F]FDG avid, [18F]FDG PET can be
applied to monitor the disease and may have additional value
for response evaluation of targeted therapy [90–93]. In
mRCC, a significant decrease of [18F]FDG uptake has been
Fig. 3 Contrast uptake curve obtained by DCE-US. The slope of the
time to peak intensity correlates with blood flow, whereas the peak
intensity and area under the curve correlate with blood volume
(reproduced with permission, © Springer-Verlag 2007 [70])
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measured in patients treated with either sunitinib or sorafenib
[92, 93]. In a recent study, 12 mRCC patients underwent
[18F]FDG PET to assess tumor response to sunitinib [93].
After the first treatment cycle, there was a decrease in the
maximum standardized uptake value (SUVmax) of 17%
(range; −59% to +100%), while the sum of the target lesions
remained unchanged [93]. In two out of 12 patients, a non-
significant decrease in SUVmax was measured, along with a
non-significant increase in tumor size which was associated
with a decrease in tumor density on CT [93]. As both
patients had a long PFS (335 and 455 days), these findings
suggested that the increase in tumor size in these patients
was associated with the development of necrosis instead of
PD. In another study, combined [18F]FDG PET/CT has been
applied for assessment of tumor response in 10 mRCC
patients treated with sorafenib [92]. After 1–2 months of
sorafenib treatment, the mean and maximum [18F]FDG
uptake in all lesions decreased to, respectively, 75% (range;
32–105%) and 86% (range; 46–131%) of the baseline value
[92]. Sorafenib appeared to induce a heterogeneous decrease
in [18F]FDG uptake in tumor lesions [92], suggesting that
volumetric measurements may have additional value to
determine tumor response in individual lesions. Both studies
described above had performed [18F]FDG PET scanning
after the first treatment cycle, but this technique may already
be able to detect a metabolic response within 1 week as has
been demonstrated for imatinib-treated GIST lesions [94,
95]. Indeed, an early metabolic response by [18F]FDG PET
was reported within 2 weeks of therapy in a mRCC patient
treated with semaxanib (SU5416) [90]. [18F]FDG PET has
not yet been evaluated in mRCC patients on treatment with
mTOR inhibitors, but early inhibition of [18F]FDG uptake
has been noted in patients with non-small cell lung cancer
who were treated with everolimus [96]. This suggests that
[18F]FDG PET may also be useful to assess metabolic
response in mRCC patients treated with mTOR inhibitors.
Although the role of [18F]FDG PET for response
evaluation of targeted therapy is expanding [92, 93, 96,
97], [18F]FDG PET scanning is not incorporated in com-
monly used response evaluation criteria. According to
A B
C D
Fig. 4 An example of DCE-US in a patient with renal cell cancer
treated with a combination of a mTOR inhibitor and bevacizumab.
DCE-US of hepatic metastases before treatment (a, c) and on day 7 (b,
d) demonstrating necrosis. c and d represent the corresponding
contrast uptake curves before treatment and on day 7 (reproduced
with permission, © Springer-Verlag 2010 [72])
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RECIST, however, the use of [18F]FDG PET imaging is
accepted as an adjunct to determination of progression [23].
The PET Criteria in Solid Tumors (PERCIST) version 1.0
has been proposed for metabolic tumor response assessment
and serves as a starting point for PET-based response
evaluation in clinical trials [98]. To ensure that PET images
are acquired and interpreted optimally, [18F]FDG PET scans
should be performed according to guidelines that provide a
minimum standard for acquisition and require a common
quality control and quality assurance [99].
Other tracers for positron emission tomography
Besides the most commonly used PET tracer [18F]FDG, other
PET tracers have been developed for use in patients with
malignancies. The accumulation of the PET tracer [11C]
acetate in tumor cells is related to the highly active lipid
metabolism in the cell membrane associated with tumor
growth. [11C]acetate is channeled into the tricarboxylic acid
cycle via acetyl coenzyme A and then incorporated into the
cell membrane’s phospholipids. In malignancies, high uptake
of [11C]acetate was first reported in RCC [100, 101].
Currently, [11C]acetate PET has been introduced as a new
modality for imaging prostate cancer and its metastases
[102]. In a RCC case report, uptake of [11C]acetate in a non-
[18F]FDG-avid hepatic metastasis has been described, which
showed a reduction in [11C]acetate uptake after only 2 weeks
of sunitinib treatment [103].
With regard to the high vascularization in RCC lesions,
quantification of tumor perfusion using radioactive water
(H2
15O) may be used to monitor antiangiogenic treatment
[91, 104–106]. The injected radioactive water is freely
diffusible in tissue [107] and a time-activity curve (TAC)
reflecting 15O accumulation in tumors can be generated
[108, 109]. The short half-life of radioactive oxygen
(~2 min) enables serial measurements within a single scan
session, but requires the presence of a nearby cyclotron for
probe preparation.
Proliferation is an important feature of tumors and can be
visualized using 3-deoxy-3-[18F]fluorothymidine ([18F]
FLT) [110]. In patients with recurrent gliomas treated with
bevacizumab and irinotecan, [18F]FLT PET seemed to be an
early marker of OS, which was already predictive at 1–
2 weeks after the start of treatment [111]. Although [18F]
FLT uptake was measured in renal transitional cell
carcinoma [112], it is currently unknown whether [18F]
FLT uptake is a common characteristic of RCC.
Radiolabeled targeted agents
As the PET technique is able to quantify tracer concentrations
in absolute units, radiolabeling of targeted agents with short-
lived positron-emitting radionuclides, such as carbon-11 [11C]
(half-life: 20.4 min) and fluorine-18 [18F] (half-life:
109.8 min), is an attractive approach to assess their uptake
in tumor lesions. In dynamic PET studies, the optimal kinetic
model of an injected tracer can be developed to quantify the
tumor uptake of the radiolabeled drug [113]. Currently,
several targeted drugs have been radiolabeled as PET tracers
and their number is still increasing [114]. These specific PET
tracers provide a unique opportunity for personalized
treatment planning, since they may be able to predict tumor
response before initiation of therapy [114]. Of the targeted
agents for treatment of mRCC, [89Zr]bevacizumab and [18F]
sunitinib have been developed as PET tracers [115, 116].
PET studies with [89Zr]bevacizumab [117] and [18F]sunitinib
may not only be used to explore a potential relationship
between pre-treatment uptake and response, but might also
give insight into drug uptake during treatment and the
development of tumor resistance.
Response evaluation of targeted therapy at specific
tumor sites
Primary tumor
Up to 30% of patients with mRCC present with metastatic
disease. In the era of immunotherapy, response of the
primary tumor to cytokine-based therapy was very rare
[118–120]. Therefore, patients with mRCC and a resectable
primary tumor in situ usually underwent cytoreductive
nephrectomy. This treatment strategy was based on the
results from two randomized phase III clinical trials
demonstrating a longer OS in patients with nephrectomy
followed by interferon-α versus patients on interferon-α
alone [121–123]. In the era of targeted therapy, however,
cytoreductive nephrectomy in patients with asymptomatic
primary tumors has become controversial [124], as
impressive drug-induced responses have been observed
in primary RCC tumors [21]. Moreover, targeted therapy
can palliate primary tumor-related symptoms, such as pain
and hematuria.
The observed responses in primary RCC lesions have
provided opportunities for new treatment approaches in
patients who present with synchronous metastases. First,
treatment with targeted agents may make cytoreductive
nephrectomy unnecessary, preventing patients from peri-
operative and post-operative complications. A prospective
randomized phase III clinical trial is underway addressing
the question whether refraining patients from nephrectomy
has an impact on their survival. Second, targeted agents can
be applied as neoadjuvant therapy to achieve downsizing of
the primary tumor that may facilitate cytoreductive ne-
phrectomy [20, 125–127]. A few treatment cycles may be
sufficient, as the optimal effect of downsizing primary
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tumors is mostly achieved in the first 3 months [21]. The
PD rate in primary tumors, however, varies from 0% to
47% [21, 128] and mixed responses between the primary
tumor and the metastases may occur, indicating that there is
a risk of progression of initially resectable primary tumors
to inoperability despite a response in metastases [129].
Therefore, appropriate response evaluation is required to
early identify mRCC patients with failure of targeted
therapy in the primary tumor. Then, when patients develop
PD in resectable primaries in the presence of stable disease
in metastases, the treatment plan can be changed rapidly
and cytoreductive surgery can be reconsidered.
When using RECIST to determine treatment response in
patients with both a primary tumor and metastases, the
overall response in these patients may be underestimated. In
general, primary tumors of RCC have an enormous size as
compared to their metastases [130, 131]. In addition, large
primary tumors show a relatively smaller decrease in size
than their metastases during targeted therapy [21, 132].
Consequently, inclusion of large primaries in RECIST
measurements can have significant impact on the overall
objective response. For that reason, it may be preferable to
determine the response in primary tumors and metastases
separately and exclude primaries from overall response
assessment [133].
Volumetric measurements may give more insight into the
response of primary tumors during targeted therapy.We did not
find volumetric measurements of sunitinib-treated primary
tumors of additional value [21], because one-dimensional
changes in size showed a high correlation with volumetric
changes. This study indicated that changes in size of the
primary tumors can be considered symmetrical and that
RECIST measurements are sufficient for evaluation of
response to sunitinib. Note that for changes in tumor size,
the response criteria are different for one-dimensional
(RECIST), two-dimensional (World Health Organization
definitions) and three-dimensional (volumetric) measure-
ments, and a PR is reached upon a decrease in tumor size
of, respectively, 30%, 50% and 65% [23].
As targeted therapy in primary tumors is associated with
extensive tumor necrosis, assessment of changes in tumor
attenuation may be an additional indicator of response.
Targeted therapy consisting of sunitinib induced a 31%
reduction in the median volume of the primary tumor and
was accompanied by a 39% increase in the median volume of
primary tumor necrosis [21]. In addition, the median decrease
in enhancement as measured in one plane of the primary
tumor was 13% in primary tumors treated with sorafenib
[126]. With regard to changes in tumor attenuation in primary
tumors, the largest series has been described by Cowey et al.
[134]. In this retrospective study of 30 mRCC patients treated
with sunitinib or sorafenib, a positive relationship between the
loss of primary tumor enhancement and the degree of primary
tumor shrinkage was seen: a larger percentual decrease in
treatment-induced enhancement correlated with a larger
percentual decrease in primary tumor size. No relationship
was found between the pre-treatment contrast-enhancement
and the pre-treatment size of the primary tumor. There were a
few patients in whom the change in dimension did not match
the degree or direction of change in enhancement, but the
clinical significance of this discrepancy is not clear.
Lung metastases
Lung metastases can be detected in up to 80% of mRCC
patients [135]. Lung lesions can have a rather small size,
which may limit specific response measurements. As an
example, we have reported that a large number of lung
metastases was ineligible for measurement according to the
Choi criteria, as these lesions had a size <15 mm at baseline
[22]. These lesions were still eligible for measurements
according to RECIST, as their size was ≥10 mm. In
addition, assessment of tumor attenuation in lung lesions
implies a risk of unreliable mean values due to averaging of
attenuation values between soft issue and air.
Targeted therapy is known to cause air-containing cavita-
tions in lung lesions of several solid tumors, including RCC
[22] (Fig. 5). Cavitations of lung lesions are especially
common in patients with non-small cell lung cancer on
treatment with inhibitors of VEGF signaling and platinum-
based chemotherapy [136, 137]. Crabb et al. [137] have
reported that response evaluation of lung lesions may be
improved by incorporation of cavitations into the volume
assessment. Incorporation of cavitations into response
evaluation of lung metastases of mRCC is not required as
the incidence of cavitations appears to be relatively low [22,
32], likely due to their relatively small size.
Bone metastases
In RCC, the bone is the second most common site of
metastases [135]. In patients without bone metastases,
progression of the disease with respect to the bone is easily
defined by the development of any new bone lesions during
treatment. In case of pre-existent bone metastases, however,
response evaluation of targeted therapy is more difficult
[138]. Traditionally, all bone lesions were considered as
non-target lesions according to RECIST version 1.0 [23].
RECIST version 1.1 states that osteolytic bone lesions with
an identifiable soft tissue component, assessed by CT or
MRI, can be considered as measurable if the soft tissue
component otherwise meets the definition of measurability
[23]. Osteoblastic bone lesions, however, are still truly non-
measurable. Furthermore, PET scan, bone scan, or plain
films are not considered adequate imaging techniques to
evaluate bone lesions, but these modalities can be used to
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confirm the presence or disappearance of bone lesions [23,
139, 140]. Although several investigators have attempted to
validate new criteria for evaluation of bone metastases
[140], no consensus has yet been reached.
Brain metastases
Currently, contrast-enhanced MRI is the best diagnostic test
to detect brain metastases [141]. However, in patients with
mRCC brain imaging is usually performed when patients
present with central nervous system symptoms. Therefore,
the experience on evaluation of targeted therapy in brain
metastases from mRCC is mostly limited to symptomatic
brain metastases. Presently, the reports on the efficacy of
targeted therapy in brain metastases of RCC have been
conflicting. Brain metastases have been described as the
first sign of progression in mRCC patients treated with
targeted agents suggesting relatively poor penetrance into
the brain [142], whereas responses of brain metastases to
targeted therapy have also been described [143–146].
Response evaluation of targeted therapy has been mostly
performed in brain metastases that have been pretreated
with radiotherapy or surgery. This may make the interpre-
tation of brain imaging during targeted therapy more
difficult, as both radiotherapy and surgery cause radio-
graphic changes. After surgery or radiotherapy of the brain,
treatment with sorafenib and sunitinib in mRCC patients
may cause an increase in peritumoral edema and MRI
contrast-enhancement [147]. Such radiographic changes
may result from leakage of the drug across the blood brain
barrier that is already impaired by previous surgical or
radiation intervention [147]. Misinterpretation of these
radiographic changes may suggest PD and the applied
treatment as inadequate. In such cases, however, discontin-
uation of the targeted drug may lead to progressive
improvement of edema and MRI enhancement [147].
Brain metastases are associated with vasogenic cerebral
edema, which is caused by leakage of fluid from the
intravascular space into the brain parenchyma due to the
hyperpermeability of the tumor vasculature. This abnor-
mally permeable tumor vasculature is stimulated by VEGF
that is secreted by tumor cells. Therefore, targeted agents
that block the VEGF signaling pathway may be able to
reduce tumor-associated edema by decreasing vascular
permeability. In glioblastoma patients, cediranib, a TKI of
VEGFR, caused rapid and significant reduction in vaso-
genic edema which was associated with a decrease in
vascular permeability, as measured by the transfer constant
Ktrans using DCE-MRI [148]. Although DCE-MRI has not
yet been evaluated to assess the effects of targeted agents in
brain metastases from RCC, similar effects may be
expected with agents inhibiting VEGF signaling.
Clinical issues for response evaluation in renal cell
cancer
Functional imaging, such as DCE-US and dynamic PET
scans, is increasingly incorporated in the evaluation of the
efficacy of anticancer drugs. These imaging techniques
usually have a limited field of view, which may be a
disadvantage. For example, the field of view of a dynamic
PET scan is currently <20 cm. Therefore, functional
imaging can usually not be applied to evaluate the disease
in the whole patient. However, the recent trend is towards a
reduction of lesions to be measured, as RECIST version 1.1
has reduced the maximum number of target lesions from 10
to 5 [23]. Hillman et al. [149] reported that measurement of
>2 metastatic lesions did not alter the definitive response in
solid tumors. Functional imaging may fail to detect new
lesions outside the field of view in case of PD, which is a
potential limitation for routine use of these techniques. In
addition, functional imaging techniques may be significant-
ly influenced by the hemodynamic changes that are caused
by targeted agents, in particular by inhibitors of VEGF
signaling. As treatment with these drugs is associated with
A B
Fig. 5 An example of a renal
cell cancer patient with lung
metastases at baseline (a) and
pulmonary cavitations at first
response assessment during
treatment with sunitinib
(b, arrow) [22]
106 Targ Oncol (2010) 5:95–112
an increase in blood pressure [150, 151], a decrease in heart
rate [152], and a reduction in capillary density of the
normal microcirculation [153], these hemodynamic effects
may affect the kinetic parameters that are obtained by
functional imaging, such as PET and DCE-MRI. Therefore,
methods need to be developed that correct for blood
pressure and cardiac output in the kinetic modeling of
functional imaging techniques.
Before implementation of new imaging tools and
changes in response evaluation criteria to determine the
efficacy of targeted therapies in the clinic, the feasibil-
ity, accuracy and reproducibility of the new method
should be determined. For the assessment of tumor
response, the test-retest reproducibility of the method
needs to be known in order to determine the minimal
change in the variable that represents a true treatment
effect. In particular, when relatively small changes are
already considered as tumor response, the test-retest
reproducibility needs to be high. In addition, there is a
need for standardized protocols including timing of
response evaluation, acquisition of imaging data and
data analysis in order to optimally compare the results
in individual patients at different time-points, but also
to enable exchange of data among different institutions.
With regard to the timing of response assessment,
specific attention should be paid to sunitinib, as this
TKI is usually administered in a schedule consisting of
4 weeks on treatment followed by a 2-week rest period
[154]. Since temporary discontinuation of sunitinib may
result in flare-up mimicking PD [155], response measure-
ments should not be performed during the rest period.
Conclusions
As targeted therapy causes disease stabilization rather than
substantial tumor regression, new response criteria and
imaging techniques have recently been developed for evalu-
ation of the efficacy of these molecules in mRCC patients.
RECIST is usually applied to assess tumor response in mRCC
and is able to identify patients with clinical benefit. However,
RECIST is not able to early identify mRCC patients with a
poor PFS during targeted therapy. Incorporation of treatment-
induced changes in tumor attenuation on contrast-enhanced
CT may have additional value to assess tumor response, but it
is not clear whether inclusion of these changes in decision-
making has significant impact on the current management of
mRCC patients. Functional imaging techniques including
DCE-CT, DCE-MRI, DCE-US and PET are under investiga-
tion for response evaluation in mRCC. The first reports are
promising, but further studies are required to validate the
usefulness of these imaging techniques in mRCC patients
early during targeted therapy.
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